Next Article in Journal
Evolving Therapeutic Strategies to Exploit Chromosome Instability in Cancer
Next Article in Special Issue
Eukaryotic Elongation Factor 2 Kinase (eEF2K) in Cancer
Previous Article in Journal
CAR-T Cell Therapy: From the Bench to the Bedside
Previous Article in Special Issue
Regulation of mTOR, Metabolic Fitness, and Effector Functions by Cytokines in Natural Killer Cells
Article Menu
Issue 11 (November) cover image

Export Article

Open AccessFeature PaperReview
Cancers 2017, 9(11), 152;

Evolving Significance and Future Relevance of Anti-Angiogenic Activity of mTOR Inhibitors in Cancer Therapy

Department of Visceral Surgery, Lausanne University Hospital, Pavillon 4, avenue de Beaumont, 1011 Lausanne, Switzerland
Author to whom correspondence should be addressed.
Academic Editors: Andrew R. Tee and James Murray
Received: 4 September 2017 / Revised: 23 October 2017 / Accepted: 27 October 2017 / Published: 1 November 2017
(This article belongs to the Special Issue mTOR Pathway in Cancer)
Full-Text   |   PDF [1089 KB, uploaded 1 November 2017]   |  


mTOR inhibitors have demonstrated remarkable anti-tumor activity in experimental models, mainly by reducing cancer cell growth and tumor angiogenesis. Their use in cancer patients as monotherapy has, however, generated only limited benefits, increasing median overall survival by only a few months. Likewise, in other targeted therapies, cancer cells develop resistance mechanisms to overcome mTOR inhibition. Hence, novel therapeutic strategies have to be designed to increase the efficacy of mTOR inhibitors in cancer. In this review, we discuss the present and future relevance of mTOR inhibitors in cancer therapy by focusing on their effects on tumor angiogenesis. View Full-Text
Keywords: mTOR; tumor angiogenesis; rapalogs; cancer; endothelial cell mTOR; tumor angiogenesis; rapalogs; cancer; endothelial cell

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Faes, S.; Santoro, T.; Demartines, N.; Dormond, O. Evolving Significance and Future Relevance of Anti-Angiogenic Activity of mTOR Inhibitors in Cancer Therapy. Cancers 2017, 9, 152.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top